Rosie Collington is a Junior Researcher with the Academic-Industry Research Network and MSc student at the University of Copenhagen. She has previously worked in health policy and advocacy at medical research and patient organizations in the UK.
By this expert
Contrary to pharmaceutical company claims, revenue from high insulin prices are going to shareholders, not R&D
This paper considers the relationship between profits realized from higher insulin list prices, pharmaceutical innovation, and the financial structures of the three dominant insulin manufacturing companies, which set list prices.
Featuring this expert
Evidence shows pharmaceutical companies won’t stop price-gouging and risking American lives for financial gain in this time of crises – unless we force them.